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Abstract
Background—The prognostic value of occurrence of ischemic stroke in a patient despite aspirin 
treatment (aspirin treatment failure) is not known. Our objective was to determine if aspirin 
treatment failure predicts recurrent ischemic stroke and/or death.
Methods—We performed a post-hoc analysis of data from the National Institute of Neurological 
Disorders and Stroke (NINDS) intravenous recombinant tissue plasminogen activator (rt-PA) trial 
and the Trial of ORG 10172 in Acute Stroke Treatment (TOAST). Multivariate analysis was used 
to calculate the odds ratio (OR) of recurrent stroke and recurrent stroke or death for aspirin 
treatment failure patients for the duration of available follow-up (3 months for TOAST patients; 12 
months for NINDS rt-PA trial patients).
Results—The rate of aspirin treatment failure was 40% and 35% among 1275 patients and 624 
patients recruited in the TOAST and NINDS rt-PA trials, respectively. The risk of stroke and death 
at 3 months and 1 year was not higher among patients classified as aspirin treatment failures 
among the TOAST (OR 1.1; 95% confidence interval [CI] 0.8–1.6; P =.7) or NINDS rt-PA trial 
patients (OR 0.8; 95% CI 0.6–1.3; P =.4), respectively. In subgroup analysis, aspirin treatment 
failure was not found to be associated with recurrent stroke or with the combined endpoint of 
stroke and death among categories defined by etiologic subtype, including those with large artery 
atherosclerosis.
Conclusions—In a post-hoc analysis of 2 randomized ischemic stroke trials, aspirin treatment 
failure was not found to be associated with an increased risk of recurrent stroke or death.
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Aspirin treatment failure is a clinical term that refers to the recurrence of thromboembolic 
events in patients treated with aspirin.1 Aspirin use has been shown to reduce the risk of 
serious vascular events (nonfatal myocardial infarction, nonfatal stroke, or vascular death) 
by approximately 25%.2 If the analysis is restricted to patients with cerebrovascular disease, 
the relative risk reduction is 13%.3,4 Among patients with vascular disease, the annual risk 
of a serious vascular event is in the 4% to 8% range and aspirin can be expected to prevent at 
least 10 to 20 such events for every 1000 patients treated for 1 year.2,5 Subsequently, 30 to 
60 vascular events should be expected to occur among every 1000 patients on aspirin over 
the course of a year (treatment failure). The pathophysiologic basis of ischemic events that 
occur during treatment with aspirin is unknown, but several factors, including aspirin 
resistance, platelet hyperaggregability, and reduced aspirin bioavailability have been 
proposed.6 There is a lot of variability in the manner that aspirin resistance and aspirin 
treatment failure are defined, and the terms are sometimes used interchangeably. Despite the 
lack of a concrete putative mechanism and uniform definitions, aspirin treatment failure is 
widely believed to be associated with a higher likelihood of future events, and it therefore 
affects management decisions. We undertook this study to examine whether aspirin 
treatment failure among ischemic stroke patients is associated with a higher risk of recurrent 
ischemic stroke and death.
Methods
We analyzed the data from 2 prospective, randomized controlled stroke trials, the Trial of 
ORG 10172 in Acute Stroke Treatment (TOAST)7 and the National Institute of Neurological 
Disorders and Stroke (NINDS) recombinant tissue plasminogen activator (rt-PA) trial.8 The 
TOAST dataset was acquired from the investigators following permission from the NINDS, 
and for the NINDS rt-PA trial, the public access data files available from National Technical 
Information Services (Springfield, VA) were used. The design and primary results of the trial 
have been presented in detail in previous publications.8–10
Briefly, TOAST tested the efficacy of the low–molecular weight heparinoid ORG 10172 
(daparinoid) in acute ischemic stroke. The study randomized 1281 patients over the course 
of 6 years. Classification of stroke subtype was based on a central-blinded evaluation 
assessing the clinical findings and the results of brain imaging and ancillary diagnostic tests. 
Categories were large artery atherosclerosis, cardioembolism, small artery occlusion, other 
determined cause, and undetermined cause.11 A 7-day course of daparinoid or placebo was 
administered within 24 hours from stroke onset. The main outcome measure was the rate of 
favorable outcome at 3 months, defined as the combination of a Glasgow Outcome Scale 
score of I or II and a modified Barthel Index ≥12 at 3 months or 7 days. Patients were 
assessed daily during the acute treatment period and had a follow-up examination at 3 
months.
The NINDS rt-PA stroke trial was a randomized trial of intravenous (IV) rt-PA for acute 
ischemic stroke. The trial was conducted in 2 parts. First, 291 patients were randomized to 
receive either placebo or 0.9 mg/kg IV rt-PA within 3 hours of stroke onset. The goal was to 
test the efficacy of rt-PA at 24 hours after stroke onset, but clinical data were also collected 
at 3 months. Subsequently, 333 patients were randomized to test the effect of rt-PA on 
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favorable outcome at 3 months measured by a global outcome scale derived from the 
combination of 4 existing scales (modified Rankin Scale [mRS], Glasgow Outcome Scale, 
Barthel Index, and National Institutes of Health Stroke Scale [NIHSSS] score). Clinical data 
were collected at baseline, 24 hours, and 3 months after randomization. In a follow-up 
study,9 outcome data on all 624 patients were collected by means of telephone interviews at 
6 and 12 months after stroke onset. Stroke subtypes were determined based on the TOAST 
criteria.11
Statistical Analysis
We sought to evaluate the effect of aspirin treatment failure on outcome by the end of 
available follow-up after the initial stroke. The patients who had been taking aspirin at the 
time of their stroke (at least 7 days earlier in TOAST, and before randomization in NINDS) 
and would therefore be characterized as aspirin treatment failures were compared to those 
who were not taking aspirin. The outcome measures were occurrence of any stroke and the 
combined endpoint of stroke and/or and death at 3 months for the TOAST patients and at 1 
year for the NINDS rt-PA trial patients.
For each study, we compared the distribution of demographics, cardiovascular risk factors, 
severity (NIHSS score on admission), and etiology of stroke between the patients who had 
previously been taking aspirin and those who had not taken aspirin. Data are presented as 
percent or mean ± SD. The Chi-square test was used for comparing categorical data, and the 
t test was used for continuous data. The effect of previous aspirin use on outcomes was 
evaluated using multivariate logistic regression. For this analysis, we considered all variables 
that differed between the 2 groups and included those that had an association with outcome 
variables of P <.20 by univariate comparison in the final model. Stratified analysis was then 
performed according to the etiology of ischemic stroke. For this secondary analysis, our 
model only adjusted for age and initial stroke severity (NIHSS score) for the TOAST-
recruited patients and for initial NIHSS score for NINDS rt-PA trial–recruited patients 
because of sample size limitations.
Results
The TOAST trial randomized 1281 patients. Follow-up for 3 months was available for 1275 
patients, of whom 509 had been taking aspirin for at least 1 week before their stroke. The 
NINDS trial randomized 624 patients. Of those patients, 216 had taken aspirin before stroke 
onset. In both trials, the patients who had been taking aspirin were mostly men and white, 
were older, had a higher prevalence of cardiovascular risk factors with the exception of 
cigarette smoking, and had similar baseline stroke severity and frequency of stroke subtypes 
as the “aspirin-naïve” patients (Tables 1 and 2).
In univariate analysis, there was no difference in the risk of stroke between the aspirin 
treatment failure and “aspirin-naïve” patients in either the TOAST (P =.55) at 3 months or 
the NINDS rt-PA (P = .93) trial at 1 year. This finding was confirmed in multivariate 
analysis. After adjusting for age, gender, baseline NIHSS score, history of previous stroke, 
congestive heart failure, and hypertension, aspirin failure among the TOAST-recruited 
patients was not associated with stroke recurrence at 3 months (odds ratio [OR] 1.06; 95% 
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confidence interval [CI] 0.63–1.80; P = .82; Fig 1). The same lack of association was 
observed among the NINDS rt-PA trial–recruited patients after adjusting for age, baseline 
NIHSS score, history of previous stroke, hypertension, cigarette smoking, and coronary 
artery disease (OR 0.88; 95% CI 0.40–1.93; P =.74; Fig 1).
Univariate analysis revealed no association between aspirin treatment failure with regard to 
the combined endpoint of stroke and death in the patients recruited in TOAST (P = .54) and 
those recruited in the NINDS rt-PA trial (P =.61). Multivariate analysis was performed 
adjusting for the same variables for each study as listed above. The association between 
aspirin treatment failure and stroke and/or death was not significant among the TOAST 
patients within 3 months (OR 1.09; 95% CI 0.75–1.58; P =.67) or the NINDS rt-PA patients 
(OR 0.84; 95% CI 0.55–1.28; P =.42) within 1 year (Fig 1).
In subgroup analysis (Tables 3 and 4), no association between aspirin treatment failure and 
both outcome measures could be identified in any of the stroke subtypes defined by stroke 
etiology. In multivariate analysis, we adjusted for patient age and baseline NIHSS score for 
the TOAST-recruited patients and for baseline NIHSS score for the NINDS rt-PA–recruited 
patients. Aspirin treatment failure was not associated with stroke or the combined stroke and 
death endpoint in any of the stroke subtypes, including large artery atherosclerosis, in either 
trial (Tables 3 and 4).
Discussion
Aspirin treatment failure among ischemic stroke patients is widely believed to be associated 
with a higher likelihood of future ischemic events. In this post-hoc analysis, however, we did 
not observe an increase in the risk of recurrent stroke or death among patients who failed 
aspirin therapy.
Aspirin resistance, broadly defined as an inadequate protective effect of aspirin, is the 
phenomenon most commonly implicated as a cause of aspirin treatment failure. Aspirin 
resistance can be assessed by a variety of methods that measure platelet aggregation ex vivo 
or by measuring levels of thromboxane A2 metabolites. Numerous studies have found 
aspirin resistance to correlate with higher risk of subsequent events among patients with 
cardiovascular disease,12 peripheral vascular disease,13 and stroke.14,15 This finding has 
been confirmed for cardiac patients in several metaanalyses.16
Still, the clinical significance, and even the true prevalence of aspirin resistance remains a 
subject of debate.17 The prevalence of aspirin resistance among vascular patients has been 
reported at widely divergent rates.18,19 Differences in the techniques used account for part of 
the variability in the results. Using different assays, Lordkipanidze et al20 found that the 
prevalence rates of aspirin resistance changed from 2.8% to 59.5% for the same cohort of 
201 patients with stable coronary artery disease. Studies have used different aspirin dosing 
regimens,21 even though aspirin resistance has been shown to be dose-dependent and 
reversible in some individuals by using higher aspirin doses.21,22 Patient noncompliance is 
frequent,23 and there has been no uniform definition of aspirin resistance.24 Finally, it 
appears that aspirin resistance is a dynamic phenomenon that can develop in the course of 
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treatment even though initially absent,25,26 and be brought on by conditions that are 
associated with higher platelet activation, such as inflammation.24
Until now, very few studies have reported on aspirin treatment failure in the context of the 
prevention of recurrent stroke. Most of the available data on the clinical significance of 
aspirin treatment failure stem from post-hoc analyses from 3 major multicenter, double-
blind, randomized stroke trials: Warfarin-Aspirin Symptomatic Intracranial Disease 
(WASID),27 Warfarin-Aspirin Recurrent Stroke Study Group (WARSS),28 and Ticlopidine 
Aspirin Stroke Study Group (TASS).29 In TASS, the rate of recurrent stroke was estimated 
for 3034 patients during a 2- to 6-year period after randomization to aspirin or ticlopidine. 
The risk of recurrent stroke was higher (12%) in the 1297 patients who had previously been 
treated with aspirin. Post-hoc analysis also revealed that patients who had been taking 
aspirin at the time of their qualifying event were among those who were most likely to 
benefit from ticlopidine.30
WARSS randomized 2206 patients with different stroke etiologies to aspirin or warfarin and 
followed them for 2 years. Post-hoc analysis revealed higher rates of stroke and death among 
the patients who were on aspirin at the time of randomization.31
WASID enrolled 569 patients with symptomatic intracranial disease.27 The patients received 
either aspirin or warfarin and were followed up for a mean of 1.8 years. Forty six percent of 
those patients were on an antiplatelet agent at the time of their qualifying event. In post-hoc 
analysis, aspirin treatment failure did not predict future stroke (OR 1.01; 95% CI 0.58–1.77; 
P =.97) or future stroke or vascular death (OR 0.86; 95% CI 0.55–1.34; P =.51).32
Based on these data, one could reason that patients with symptomatic intracranial disease 
form a subset where aspirin treatment failure does not predict future stroke. However, our 
results revealed that aspirin treatment failure was not associated with stroke or stroke and 
death at 1 year among the NINDS rt-PA trial–recruited patients and at 3 months among the 
TOAST-recruited patients, regardless of stroke etiology. Both studies in our analysis 
included patients immediately after stroke onset, unlike TASS, WARSS, and WASID. This 
recruitment paradigm allows for the ascertainment of early recurrent stroke or death. 
Because the rates of early stroke recurrence are substantial, especially among patients with 
large vessel disease,33,34 the current analysis is likely to have produced more accurate data.
Our study has a number of limitations. First, we do not know the proportion of patients who 
continued aspirin treatment following the initial treatment failure and those who were started 
on a different antithrombotic treatment. The fact that the TOASTand NINDS rt-PA trials 
were conducted in the 1990s was advantageous to our purpose because treatment options 
were more limited at that time, and therefore variability in the treatment of the patients 
during the follow-up period should have been relatively low. We could also not account for 
the effect that potential risk factor modifications and use of other medications could have 
modified the outcome of some of the patients. Our study is a secondary analysis of 
completed randomized trials. Data on some important variables may be missing, so we 
cannot exclude the possibility that unmeasured confounding could explain some of our 
findings. Because of strict inclusion and exclusion criteria in both studies, there is concern 
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that the studied patients might not be representative of the overall ischemic stroke patient 
population. The relatively small number of patients within various subgroups is another 
reason to be cautious with extrapolating our results to the general population of patients with 
ischemic stroke. The length of available follow-up for the TOAST patients was relatively 
limited, so it is conceivable that a significant number of events were not recorded. However, 
the only available data on early stroke recurrence in aspirin treatment failure patients 
revealed that 50% of the events occurred within 36 days from the initial stroke.35 Despite 
those limitations, the information this study provides may be useful to clinicians discussing 
prognosis with stroke patients who have been taking aspirin and may help guide the design 
of future clinical trials.
Many questions remain unanswered regarding the significance of aspirin resistance and 
treatment failure. Future studies should further address the following questions: (1) How 
prevalent and reliable a finding is aspirin resistance? (2) Does aspirin resistance predict 
aspirin treatment failure? (3) Does aspirin treatment failure predict future clinical events?
At this time, aspirin remains the single most cost effective and widely used agent for the 
prevention of atherothrombotic ischemic events. There are currently not sufficient data to 
support changing antiplatelet regimens or favoring endovascular procedures in aspirin 
treatment failure patients.
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(A) Stroke. (B) Stroke and/or death. Effect of aspirin treatment failure on stroke and stroke 
and death at 3 months (TOAST) and 1 year (NINDS rt-PA trial). OR, odds ratio; CI, 
confidence interval; TOAST, trial of ORG 10172 in acute stroke treatment; NINDS rt-PA, 
National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen 
trial.
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Table 1
Patient demographics, cardiovascular risk factors, and stroke subgroups based on etiology according to the 
TOAST study
Patients taking aspirin before recruitment* Patients not taking aspirin P value
No. of patients 509 766
Age, y (mean ± SD) 67 ± 10 64 ± 12 <.0001
Women 189 (37%) 313 (41%) .02
Race/ethnicity
 White 357 (71%) 440 (57%) <.0001
 African American 101 (20%) 189 (25%)
 Hispanic 38 (7%) 95 (12%)
 Asian 5 (1%) 29 (4%)
 Other 8 (2%) 13 (2%)
Mean NIHSS score at baseline (± SD) 7.9 ± 5.2 8.8 ± 5.8 .13
Active trial treatment 250 (49%) 384 (50%) .72
History of stroke 144 (28%) 85 (11%) <.0001
History of atrial fibrillation† 64 (13%) 35 (5%) <.0001
History of myocardial infarction 153 (30%) 79 (10%) <.0001
Congestive heart failure 65 (13%) 53 (7%) .0005
Diabetes 161 (32%) 210 (27%) .2
Hypertension 362 (71%) 483 (63%) .01
Hypercholesterolemia 157 (31%) 134 (17%) <.0001
Cigarette smoking 176 (35%) 321 (42%) .03
Etiology of stroke‡
 Large vessel disease 255 (33%) 159 (32%) .15
 Cardioembolic 94 (12%) 81 (16%)
 Lacunar 311 (41%) 209 (41%)
 Other 104 (14%) 55 (11%)
Abbreviations: NIHSS, National Institutes of Health Stroke Scale; SD, standard deviation; TOAST, Trial of ORG 10172 in Acute Stroke Treatment.
Aspirin treatment failure patients are compared to patients who were not on aspirin. Data taken from the Trial of ORG 10172 in Acute Stroke 
Treatment.
*
Aspirin intake for a minimum of 7 days before randomization.
†
Data only partially available.
‡
Data missing for 8 patients.
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Table 2
Patient demographics, cardiovascular risk factors, and stroke subgroups based on etiology according to the 
NINDS intravenous recombinant tissue plasminogen trial
Patients taking aspirin before recruitment Patients not taking aspirin P value
No. of patients 216 408
Age, y (mean ± SD) 69 ± 11 66 ± 12 .0005
Women 85 (39%) 177 (43%) .33
Race/ethnicity
 White 154 (71%) 249 (61%) .04
 African American 44 (20%) 125 (31%)
 Hispanic 5 (1%) 7 (2%)
 Asian 15 (7%) 22 (5%)
 Other 2 (1%) 5 (1%)
Mean NIHSS score at baseline (± SD) 14.4 ± 7 15 ± 7.2 .31
Active trial treatment 127 (59%) 185 (45%) <.0001
History of stroke 47 (22%) 36 (9%) <.0001
History of atrial fibrillation 50 (23%) 65 (16%) .03
History of myocardial infarction 60 (29%) 71 (18%) .002
Congestive heart failure 36 (17%) 63 (15%) .69
Diabetes 53 (25%) 78 (19%) .11
Hypertension 155 (72%) 253 (62%) .01
Hypercholesterolemia 59 (33%) 82 (24%) .05
Cigarette smoking 58 (27%) 157 (38%) .004
Etiology of stroke
 Large vessel disease 36 (17%) 89 (22%) .37
 Cardioembolic 91 (42%) 150 (38%)
 Lacunar 23 (11%) 38 (10%)
 Other 65 (30%) 123 (31%)
Abbreviations: NIHSS, National Institutes of Health Stroke Scale; NINDS, National Institute of Neurological Disorders and Stroke; SD, standard 
deviation.
Aspirin treatment failure patients are compared to patients who were not on aspirin. Data from the NINDS intravenous recombinant tissue 
plasminogen study.
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